In gastric cancer, agents such as the anti-HER2 antibody trastuzumab, the anti-angiogenic drugs ramucirumab and apatinib, and the CLDN18.2-directed monoclonal antibody zolbetuximab have ushered in an era of personalized treatment. This evidence concerns the gene ERBB2 and gastric cancer.